Toronto lawyer donates $10 million to Sunnybrook's OCD program

Brian Reeve, a Toronto lawyer and private equity investor, has given $10 million to Sunnybrook to expand obsessive-compulsive disorder research and treatment after receiving care there in 2019. Sunnybrook says the gift will fund a permanent Reeve OCD Centre at its Bayview campus and support program expansion.

Brian Reeve, a Toronto lawyer and private equity investor, has donated $10 million to Sunnybrook Health Sciences Centre to expand research and treatment for obsessive-compulsive disorder (OCD). Reeve received four months of care in 2019 at Sunnybrook's Frederick W. Thompson Anxiety Disorders Centre and said the treatment gave him a life reset. The Thompson Centre opened in 2012 after a previous $10-million donation and Sunnybrook reports it is the only Canadian facility specializing in OCD. Sunnybrook announced the new Bayview site will be named the Reeve OCD Centre. Key facts: - Donation amount: $10 million from Brian Reeve to expand OCD research and treatment at Sunnybrook. - Personal history: Reeve spent four months in the Thompson Anxiety Disorders Centre's OCD program in 2019 and described the care as giving him a life reset. - Centre background: The Frederick W. Thompson Anxiety Disorders Centre was established in 2012 after a $10-million gift and is described by Sunnybrook as the only specialized OCD facility in Canada. - Program reach: Nearly 400 patients have been treated through the centre's intensive live-in and day programs. - Planned change: The gift will accelerate the expansion and relocation of the centre's 24/7 OCD treatment unit to Sunnybrook's Bayview campus, to be named the Reeve OCD Centre. - Prevalence note: Sunnybrook estimates OCD affects about 400,000 Canadians. Summary: Sunnybrook says the donation will accelerate the move to a permanent Bayview location and support research and specialized services under the Reeve OCD Centre name. Hospital leadership stated the centre will advance specialized OCD care and support innovative treatments for patients and families. Specific timelines and operational details for the relocation were not provided in the announcement.